I bought the shares as a bet when the market was so expensive that I couldn't find anything more attractive. now there are some shares from my portfolio and also on the watchlist that I have more hope for in the long term, so I'm switching to other stocks when the market has calmed down a bit📈

Hello everyone,

My name is Antonio, I'm almost 27 years old and I'm from Bremen. I currently work as a train manager at Deutsche Bahn. Anyone who knows the job knows that chaos is almost guaranteed here. If a train is on time, everyone wonders what's going wrong. Delays, strikes, unforeseen events - you get used to the fact that nothing goes as expected. And that's exactly how I felt on the stock market: constantly chasing hypes, always on the lookout for quick profits, and in the end I never knew whether the train was still on the right track. I experienced just as much chaos on the markets as I did in my day-to-day work - but fortunately I've learned from it and am now looking for a fresh start where everything is a bit more orderly and predictable.

I've made a lot of mistakes on the stock market in the past. And not too few - unfortunately. Like many of you, I had the idea that the stock market would make me a quick buck. I let myself be led by hypes, trends and the desire for immediate results. I wasn't interested in investing for the long term or building a solid foundation for the future, I was only ever interested in making a quick profit. Leveraged products, knock-out certificates - it was all there. It felt like a casino where the loss was usually the only "win". And so it came as it had to: I not only lost money, but also confidence in my own decisions and the markets.

But today, in 2025, I have realized that it is time for a fresh start. I have learned from my mistakes. It's been a long road and I've thought a lot about why I was so quick to go for the quick buck instead of investing patiently and focusing on long-term success. I learned the lessons I needed to become a better investor. Patience, diversification and a long-term perspective are now my principles. I want to create something tangible, not just a portfolio full of numbers, but also a solid, long-term strategy that will help me to continuously build my wealth.

My portfolio: A solid foundation

The portfolio I have now built up is a mix of different asset classes and asset classes. My aim is to diversify broadly and not miss out on potential growth opportunities, while spreading risk across different sectors and regions. Here is an overview of what my investment strategy looks like:

ETFs (€1000/month)

I have deliberately opted for a broad diversification and invested in different geographical regions and markets. This diversification should ensure that my capital benefits from the markets that have the greatest potential in the coming decades.

- IE00BMTX1Y45 ( $I500) (-0.33%)

- LU0908500753 ( $MEUD (+0.95%) )

- IE00BYXVGY31 ( $FUSA (+0.6%) )

- IE00BD1F4M44 ( $IUVF (+0.96%) )

- IE00BKM4GZ66 ( $EIMI (-0.16%) )

- LU1681041973 ( $CD9 (+1.97%) )

- LU0486851024 ( $D5BL (+1.01%) )

- IE00BYQCZN58 ( $DXJZ (+0.5%) )

- IE00BF4RFH31 ( $WSML (-0.07%) )

- IE00BG0SKF03 ( $5MVL (-0.03%) )

- IE00B652H904 ( $SEDY (+0.04%) )

- LU2089238385 ( $PRAJ (+0.3%) )

- DE000A0H0744 ( $EXXW (-0.09%) )

- IE00BFXR5W90 ( $LGAG (-2.27%) )

- LU0779800910 ( $XCHA (-0.81%) )

- HANetf Future of Defense UCITS ETF ($ASWC (-1.79%) )

So many ETFs? Does he still have all his wits about him?

Some people will think exactly that when they look at my ETF list. And yes, I admit that the portfolio is pretty broadly based - perhaps too broad for some. But that's exactly my goal. I don't want to catch the one sector or the one region that is going through the roof. I want to have everything! If a market explodes somewhere in the world, then I want to be there. Be it through large caps, small caps, growth, value, technology or emerging markets, my approach is not to miss out on potential opportunities and at the same time not to put all my eggs in one basket. Some call it overdiversification, I call it my personal "all-world approach"

The idea behind the selection of these ETFs is that I want to focus on global markets and growth regions without missing out on important sectors such as technology, healthcare and energy. The USA (with over 55% of my portfolio) remains the central component due to its economic importance and innovative strength. At the same time, I am also focusing on Europe, Asia, China and emerging markets, which are increasingly among the growth markets of the future. Small caps also play a key role for me, as they often have the potential to grow faster and offer opportunities that are often overlooked by the large institutions.

Cryptocurrencies (€100/month in Bitcoin ( $BTC (-0.37%) ) €50/month in Ethereum ($ETH) (-1.07%)

I also invest in Bitcoin and Ethereum as I am convinced of the future of these digital currencies. Even if the volatility is high, I see the long-term potential of these technologies. For me, it is an opportunity to participate in the development of a new financial world.

Gold (50 €/month EUWAX Gold ($DE000EWG0LD1 (-0.31%) )

In uncertain times, I have realized how important it is to have conservative assets such as gold. The last few years of inflation and economic fluctuations have made me realize that gold can have a stabilizing effect, especially in times of crisis.

Individual stocks - My dividend strategy

I have also selected a few individual stocks that should not only offer me security, but also regular income through dividends. The reason for this is simple: I need something tangible, something visible. It's not just the pleasure of seeing the portfolio grow, but also the dividend that gives me the feeling of actively participating in the companies and benefiting from their success.

- 3M Co ($MMM (-1.59%) )

- Allianz ($ALV (+0.07%) )

- BioNTech ($BNTX (-2.29%) )

- Booking Holdings( $BKNG (-1.03%) )

- Coca-Cola ($KO (+0.93%) )

- LVMH ($MC (-2.24%) )

- MSCI Inc ($MSCI (-1.22%) )

- NextEra Energy($NEE (+3.4%) )

- Philip Morris ($PM (-2.47%) )

- Realty Income($O (+1.39%) )

BioNTech in particular, as a company that has promising potential not only during the pandemic but also beyond, is a long-term winner for me. Likewise NextEra Energy, which plays a key role in the renewable energy sector, and Booking Holdings, which should benefit from the global tourism trend. These companies not only pay dividends, but also show that you can benefit from a company's success with a long-term perspective.

Pension fund

I also invest in the DEVK pension fund (DE000A2PT1X3) through my employer $DE000A2PT1X3 . This fund is particularly important to me because of the generous contributions made by my employer and the solid returns. Even though the costs are somewhat higher, I see it as a long-term addition to my strategy.

Why this portfolio?

I built my portfolio this way because I believe in the potential of long-term global diversification. Rather than chasing short-term gains, I am looking for continuous value growth over many years. I want to support the right companies, benefit from promising markets and at the same time have a regular source of income through dividends.

I am no longer interested in making a quick buck. I have learned that true success in wealth accumulation lies in patience. And that's what it's all about: I want to create a solid foundation for the future - for myself, for my pension and perhaps for a house in a few years' time.

What do you think?

I'm really looking forward to hearing from you. What do you think of my strategy? Do you see any areas where I could diversify even more? Are there any asset classes or ETFs missing from my portfolio that would make sense for me? I am very keen to hear your opinions and advice.

Thank you for taking the time to read my story and strategy! I look forward to your feedback.

Best regards,

Antonio

The Mainz-based company Biontech $BNTX (-2.29%) is currently testing several active substances in phase 2 trials - but none have yet reached the lengthy phase 3 required for approval.

US competitor Moderna $MRNA (+3.1%) claims to have an active substance - mRNA-4157 - in two phase 3 trials: as an add-on therapy against melanoma and against a certain form of lung cancer, non-small cell lung cancer (NSCLC).

The Moderna preparation mRNA-4157 (V940) could in turn be approved in the foreseeable future for the treatment of melanoma.

The active ingredient is currently being tested in two phase 3 trials - against a form of lung cancer and against high-risk melanoma. In fact, the US Food and Drug Administration nach Angaben von Moderna und Merck has announced an accelerated approval process for the drug in combination with the immune checkpoint inhibitor pembrolizumab for melanoma therapy.

https://www.n-tv.de/wissen/Krebs-koennte-mit-mRNA-Praeparaten-besiegt-werden-article25509772.html

Hello everyone,

What do you think of the Biontech share at the moment, many difficult events are hitting the German company. Do you think it would make sense to hold on or would it be better to go out with a small profit? Unfortunately, I am very confused about the whole situation.

Here is a small excerpt from an article.

( https://www.boerse-global.de/biontech-aktie-die-wissen-nichts/295203 )

Thank you in advance. 😁

#biontech
$BNTX (-2.29%)

$BNTX (-2.29%) Could BioNTech become one of the top picks for 2025?

If the results of the current studies are confirmed, BioNTech could launch the first cancer therapies on the market in 2026. You can imagine what that means. That would give the share a strong boost🚀

Even though the share price has already moved quite a bit away from the lows in the summer, it is still an interesting level!

Daily chart:

Weekly chart:

BioNTech exhibits "OUTSTANDING" financial health, supported by strong cash flow metrics.

According to BMO Capital, the safety profile of BNT324 is in line with other ADCs currently available on the market. BioNTechs
strong
financial
positionwith more cash than debt and a healthy liquidity ratio of 7.33, provides robust support for its drug development initiatives. In addition, they highlighted that the drug showed promising early efficacy results, particularly in patients with small cell lung cancer (SCLC).

BioNTech's continued Outperform rating reflects confidence in the drug's potential and its alignment with the company's development goals.

I have BioNTech in my portfolio and it is also one of the few individual stocks in my children's portfolios - the time factor plays into their hands anyway 😎🏦

Source: https://de.investing.com/news/analyst-ratings/bmo-halt-an-outperformbewertung-fur-biontechaktien-fest-93CH-2796832

For which share would you like to prepare a short analysis with an outlook next? Currently interesting are certainly $NOVO B (-1.34%) , $ASML (+1.4%) , $MSTR (-7.42%) or $BNTX (-2.29%)

Analyst updates, 26.11.

⬆️⬆️⬆️

- ODDO BHF upgrades DEUTSCHE TELEKOM from Neutral to Outperform. Target price EUR 35. $DTE (+3.04%)

- BARCLAYS raises the target price for AIRBUS from EUR 165 to EUR 166. Overweight. $AIR (-1.71%)

- BARCLAYS raises the target price for MTU from EUR 340 to EUR 356. Equal-Weight. $MTX (-4.41%)

- DEUTSCHE BANK RESEARCH raises the target price for ANGLO AMERICAN from GBP 27 to GBP 29. Buy. $AAUKF

- UBS raises the target price for ZURICH from CHF 475 to CHF 532. Neutral. $ZURN (+1.21%)

⬇️⬇️⬇️

- JPMORGAN lowers the price target for BIONTECH from USD 124 to USD 122. Neutral. $BNTX (-2.29%)

- JPMORGAN lowers the price target for MODERNA from USD 59 to USD 45. Underweight. $MRNA (+3.1%)

- UBS lowers the target price for AIR LIQUIDE from EUR 200 to EUR 195. Buy. $AI (+0.93%)

- METZLER lowers the price target for ABO ENERGY from EUR 113 to EUR 96. Buy. $AB9 (+0.41%)

- DEUTSCHE BANK RESEARCH lowers the target price for AIR FRANCE-KLM from EUR 10 to EUR 8.50. Hold. $AF

- UBS lowers the price target for UNITED INTERNET from EUR 24 to EUR 23. Buy. $UTDI (+1.63%)

Is $PFE (+1.57%) a turnaround candidate?

After the hype surrounding the corona vaccines, Pfizer is in crisis: the share price has collapsed, sales are weakening and new blockbusters are a long time coming. But what is the real situation? Is there any hope of a turnaround - or will the shares remain a construction site?

A look at the current situation

Pfizer is in a difficult situation. After peaking during the pandemic, the share price has stabilized at around 25 euros, a far cry

far from the peak values of over 40 euros. Sales in the third quarter of 2024 amounted to USD 17.7 billion - an increase of 31% compared to the previous year. However, excluding the COVID-19 products Paxlovid and Comirnaty, growth remains moderate at 14%. Pfizer is struggling to stabilize its sales in other areas, while older drugs such as Ibrance (-13%) or Xeljanz (-36%) are increasingly losing market share.

The dividend yield of around 6.5 % appears attractive at first glance, but is it sustainable? Pfizer paid out USD 7.1 billion in dividends in the first nine months of the year, while spending on research and development amounted to USD 7.8 billion. The dividend is currently still covered, but is heavily dependent on future growth impetus.

Where is the money currently coming from?

Pfizer continues to generate a large part of its revenue from products that played a key role during the pandemic. The most important sources of revenue in the third quarter of 2024 were

• 1. Paxlovid2.7 billion USD (+ 2.5 billion USD compared to the previous year).
• 2. Comirnaty (COVID-19 vaccine)1.4 billion USD (+9 %).
• 3. Eliquis (anticoagulant): USD 1.6 billion (+9 %).
• 4. Prevnar (pneumococcal vaccine): USD 1.8 billion.
• 5. Vyndaqel (treatment of transthyretin amyloidosis): USD 1.4 billion (+63 %).
• 6. Ibrance (breast cancer treatment): USD 1.1 billion (-13 %).
• 7. Xtandi (prostate cancer): USD 561 million (+28 %).
• 8. Padcev (new cancer therapy): USD 409 million.
• 9. Nurtec ODT/Vydura (migraine): USD 337 million (+45%).
• 10. Abrysvo (RSV vaccine): USD 356 million.

Comparing these figures with the previous year, it is clear that COVID-19 products continue to play a significant role, while other areas need to grow more strongly to fill the gap.

The pipeline: Hope in 108 acts?

With 108 projects in the pipeline, Pfizer has a promising basis, at least on paper. This is broken down as follows:

• Phase 1: 46 projects.
• Phase 2: 28 projects.
• Phase 3: 30 projects.
• Phase 4 (registration): 4 projects.

Products in registration

ADCETRIS (brentuximab vedotin): A therapy for diffuse large B-cell lymphoma (DLBCL). The global market for DLBCL therapies is estimated to be worth around USD 5 billion by 2027.

COVID-19 vaccine (in collaboration with $BNTX (-2.29%)
): Extension of approval for children aged 5 to 11 years in the USA. The market for COVID-19 vaccines remains significant, particularly with a focus on younger age groups.

COVID-19 vaccine (in collaboration with
$BNTX (-2.29%)
): Extension of approval for children aged 6 months to 4 years in the USA. Vaccination of this age group is crucial to contain the pandemic.

NGENLA (Somatrogon): Treatment for growth hormone deficiency in adults (in the EU as an orphan drug classified). The market for growth hormone therapies is estimated to be worth around USD 4 billion by 2025.

Although these products offer significant sales potential, it is unlikely that they alone will be sufficient for a complete turnaround of Pfizer. A sustained recovery requires a continuous pipeline of innovative products, successful launches and effective market strategies. However, the products and acquisitions can make an important contribution to the stabilization and future growth of the company.

Blockbuster of the future?

Progress in the areas of oncology, vaccines and innovative drugs such as weight loss products are particularly important. Pfizer is investing heavily in research and development, with a budget of USD 11 to 12 billion for 2024. Some of the most promising projects are

Danugliprone (Phase 2): A GLP-1 agonist for weight loss. But Pfizer is struggling with problems here: The original twice-daily formulation was discontinued due to severe side effects - nausea and vomiting - nausea and vomiting. The sufferer may think with a twinkle in his eye, 'actually works great'. But there must be gentler ways to lose weight. Pfizer is now concentrating on a once-daily dose. Results have not yet been communicated, but should come in 2024. The market for weight loss drugs is huge and could grow to over USD 50 billion by 2030, but the competition is fierce. $NOVO B (-1.34%) (Wegovy, Ozempic) $LLY (-5.26%) (Orforglipron) are already leading the way here.

mRNA combivaccines (COVID-19 and influenza - phase 3)This vaccine is in phase 3 and, if successfully approved, could become a sales driver as the market for combined vaccines is estimated at over USD 10 billion.

Oncology therapies (phase 3): Pfizer is working on several cancer therapies, including Talzenna (prostate cancer) and Braftovi/Mektovi (lung cancer). Both are in phase 3 and could generate initial sales from 2025.

Abrysvo (RSV vaccine - Approved)This vaccine is already approved and addresses a market that is expected to grow to over 8 billion USD by 2027.

The challenges: Competition and problems

Despite its promising pipeline, Pfizer faces a number of obstacles. Especially in the area of weight loss drugs, the competition from Novo Nordisk and Eli Lilly is immense. With Semaglutide (Ozempic/Wegovy) and Orforglipron, both companies already have established products or candidates that have performed excellently in clinical trials. Pfizer must make rapid progress here to avoid falling further behind.

Another problem is the dependence on COVID-19 products. While Paxlovid and Comirnaty continue to generate sales in the short term, demand is declining sharply as the pandemic increasingly fades into the background. Without new blockbusters, it will be difficult to compensate for these revenues.

Conclusion: Is Pfizer a turnaround candidate?

The answer is: Yes, but with conditions. With innovative products such as Danuglipron and new cancer therapies, the pipeline certainly offers potential, but Pfizer is under immense pressure. The competition is strong and time is running out - especially in the field of weight loss drugs. The dividend is also only secure in the long term if new products are successfully launched on the market.

Pfizer has the resources to achieve a turnaround, but investors need patience. If the company achieves initial success with its new drugs in 2025 or 2026, the share price could recover. Until then, however, it remains a shaky candidate - with a lot of risk, but also a lot of potential.

If you've made it this far, I look forward to seeing you on the website or on Instagram. Thank you :)

Continue on my website

https://www.dividenden-rechner.de/

https://www.instagram.com/p/DCeo-cCiHPW/?img_index=1

Analsyst updates, 08.11.

⬆️⬆️⬆️

- GOLDMAN upgrades BIONTECH from Neutral to Buy and raises price target from USD 90 to USD 137. $BNTX (-2.29%)

- BOFA raises target price for UNDER ARMOUR from USD 9 to USD 13. Neutral. $UAA (+1.56%)

- DEUTSCHE BANK RESEARCH raises the price target for DELIVERY HERO from EUR 29 to EUR 35. Hold. $DHE

- DEUTSCHE BANK RESEARCH raises the price target for SIEMENS from EUR 197 to EUR 200. Buy. $SIE (-1.47%)

- JEFFERIES raises the price target for HOCHTIEF from EUR 135 to EUR 138. Buy. $HOT (-5.91%)

- DEUTSCHE BANK RESEARCH raises the price target for SIEMENS HEALTHINEERS from EUR 60 to EUR 62. Buy. $SHL (+0.61%)

- DEUTSCHE BANK RESEARCH raises the price target for NORDEX from EUR 18 to EUR 19. Buy. $NDX1 (-1.4%)

- DEUTSCHE BANK RESEARCH raises the price target for RATIONAL from 832 EUR to 841 EUR. Hold. $RAA (-3.79%)

- DEUTSCHE BANK RESEARCH raises the target price for AXA from 37 EUR to 39 EUR. Buy. $CS (+0.32%)

- WARBURG RESEARCH raises the price target for BASTEI LÜBBE from EUR 11.70 to EUR 12.20. Buy. $BST (+0%)

- DEUTSCHE BANK RESEARCH raises the price target for ARCELORMITTAL from EUR 28 to EUR 29. Buy. $MT (-3.27%)

- DZ BANK raises the price target for SWISS RE from CHF 130 to CHF 140. Buy. $SREN (+0.66%)

- ODDO BHF raises the price target for HEIDELBERG MATERIALS from EUR 99 to EUR 110. Neutral. $HEI (+1.54%)

- KEPLER CHEUVREUX raises the price target for DAIMLER TRUCK from EUR 35 to EUR 41. Hold. $DTG (-1.2%)

- KEPLER CHEUVREUX upgrades REDCARE PHARMACY from Reduce to Hold. $RDC (-2.08%)

- ODDO BHF raises the price target for HENKEL from EUR 67 to EUR 73. Neutral. $HEN (+2.12%)

- ODDO BHF raises the price target for FREENET from EUR 27 to EUR 28. Neutral. $FNTN (+0.76%)

- BARCLAYS raises the target price for ABOUT YOU from EUR 3.10 to EUR 3.40. Underweight. $YOU (+0.3%)

- BARCLAYS raises the target price for NEMETSCHEK from EUR 108 to EUR 125. Overweight. $NEM (-2.98%)

⬇️⬇️⬇️

- BOFA lowers the price target for PINTEREST from USD 45 to USD 39. Buy. $PINS

- WARBURG RESEARCH lowers the price target for DAIMLER TRUCK from EUR 56 to EUR 55. Buy. $DTG (-1.2%)

- UBS lowers the price target for JCDECAUX from EUR 21.60 to EUR 18.50. Neutral. $DEC (+6.66%)

- WARBURG RESEARCH lowers the price target for ADTRAN HOLDING from EUR 9.70 to EUR 9.30. Buy. $ADTN (-4.06%)

- ODDO BHF lowers the price target for NORDEX from EUR 18 to EUR 17. Outperform. $NDX1 (-1.4%)

- BARCLAYS lowers the target price for VESTAS from DKK 99 to DKK 80. Underweight. $VWS (-1.79%)

- KEPLER CHEUVREUX lowers the price target for FRAPORT from EUR 62 to EUR 59. Buy. $FRA (+0.45%)

- BARCLAYS lowers the target price for GSK from GBP 15.50 to GBP 14.50. Equal-Weight. $GSK

- BERENBERG lowers the price target for COMPUGROUP from EUR 23 to EUR 21. Buy. $COP (+0.22%)

- BERENBERG lowers the price target for JUNGHEINRICH from EUR 41 to EUR 39. Buy. $JUN3 (+0.18%)

- JEFFERIES lowers the target price for SUSS MICROTEC from EUR 87 to EUR 75. Buy. $SMHN (-0.77%)

08.11.2024

US Federal Reserve lowers key interest rate by 25 basis points
+ Goldman raises Biontech to 'Buy' - target up to 137 dollars + Bechtle higher - remains optimistic for the final quarter + Redcare at three-year high

The US Federal Reserve has lowered its key interest rate by 25 basis points. This decision had been firmly expected on the markets. The decision was taken unanimously by the Federal Open Market Committee (FOMC). The decision, which was taken in the week of Donald Trump's re-election as US president, followed an initial cut of 50 basis points in September and will bring the key interest rate to a range of 4.50 to 4.75 percent. US Federal Reserve officials have said that these rate cuts are justified because they are more confident that inflation will return to the central bank's target and because they believe that interest rates are still high enough to dampen economic activity even after the recent cuts. "The Council judges that the risks to achieving the employment and inflation objectives are roughly balanced," the Fed's statement said. Trump's election victory has the potential to reshape the economic outlook as the Republicans' likely majority in Congress allows for a sweeping change of course on taxes, spending, immigration and trade. The changing outlook has in turn raised questions on Wall Street as to whether the Fed will change its previous expectation that interest rates could be steadily lowered over the next year or two.

The US investment bank Goldman Sachs has Biontech $BNTX (-2.29%) from "Neutral" to "Buy" and raised its price target from 90 to 137 US dollars. Analyst Chris Shibutani now includes BNT327 - an antibody that the Mainz-based company is testing against various solid tumors - in his buy recommendation published on Friday. The investment story is moving further away from the difficult-to-assess Covid vaccine market.

With Bechtle $BC8 (-1.1%) a very weak 2024 share was in demand in pre-market trading on Friday. Following the IT service provider's final quarterly figures, the shares rose by 2.7 percent in Tradegate trading compared to the Xetra closing price. An attempt to recover from the low since 2020 thus continues. So far this year, the share has lost around 28% despite the recent stabilization and a gain of 3.3% the day before. Since the record high in 2021, the share price has even more than halved. According to a trader, the business environment for Bechtle in the third quarter was characterized by challenges. The results showed a mixed picture with weak demand in the core markets of Germany and France, but solid organic growth in other international markets, and another trader emphasized that Bechtle is optimistic about the future and continues to expect an improvement in the fourth quarter. However, the first mentioned trader sees risks in the fact that public IT spending in Germany could suffer for the time being from the end of the traffic light coalition.

The good performance of the shares of Redcare Pharmacy $RDC (-2.08%) continued on Friday with a high since December 2021. The shares were already the biggest MDax gainer in 2023 and are among the better performers in the mid-cap index this year. On Friday, they rose by up to three percent to EUR 157.60 in early Xetra trading. So far this year, they have repeatedly struggled in the EUR 153 to 154 range.

Friday: Stock market dates, economic data, quarterly figures

ex-dividend of individual stocks

Apple USD 0.25

Pfizer USD 0.42

ConocoPhillips USD 0.78

Wells Fargo USD 0.4

Quarterly figures / company dates USA / Asia

07:00 Sony quarterly figures

Untimed: Baxter International quarterly figures

Quarterly figures / Company dates Europe

07:00 LEG Immobilien | Richemont Quarterly figures

07:30 Bechtle | Deutsche Wohnen Quarterly figures

08:00 Banca Monte dei Paschi | International Consolidated Airlines Quarterly figures

10:00 Freenet earnings call and strategy update until 2028

10:30 Bechtle analyst and press conference

14:00 Pernod Ricard AGM

Economic data

• 06:00 JP: Leading indicators 9/24 (preliminary)
• 08:00 DE: Domestic tourism | Truck toll mileage index October
• 09:00 DE: Bundestag, Plenum, Berlin
• 11:30 DE: Government Pk, Berlin
• 16:00 US: Consumer Sentiment Index Uni Michigan (1st survey) November FORECAST: 71.0 previous: 70.5